Blue Note Therapeutics Receives Breakthrough Device Designation for Prescription-Only Digital Therapeutic for Acute Myeloid Leukemia
Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced that the U. S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for BNT200, mehr …
xn--gtsel-kva.de/content/34124/blue-note-therapeutics-receives-breakthrough-device-designation-for-prescription-only-digital-therapeutic-for-myeloid-leukemia.html
Enterin and Their Collaborators at NIH Announce That Alpha-Synuclein, the Culprit in Parkinson's Disease, is Core and Central to Normal Immune Function
Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, announces the publication of a paper entitled “Alpha-synuclein, the culprit in Parkinson's Disease, is required for normal immune function.”, mehr …
xn--gtsel-kva.de/content/34405/enterin-and-their-collaborators-at-nih-announce-that-alpha-synuclein-the-culprit-in-parkinson-und-apos-s-disease-is-core-and-central-to-normal-immune-function.html
